Literature DB >> 11855842

Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening.

Mitsuru Ikeda1, Abesh Kumar Bhattacharjee, Takeshi Kondoh, Tatsuya Nagashima, Norihiko Tamaki.   

Abstract

The precise mechanism of reversible opening of the blood-brain barrier (BBB) is elusive. Hyperosmotic mannitol at 1.4 to 1.6 M is commonly used for this purpose but intraarterial injection of such a hyperosmotic solution is known to have possible side effects on the brain. Cooling of the solution has recently been reported to have potential to open the BBB. The in situ brain perfusion technique with [(14)C]-sucrose was used first to quantify BBB permeability in rats after intraarterial injection of 1.1 M mannitol, which is less hyperosmotic than commonly used mannitol, at room temperature and at 4 degrees C. Mannitol at 4 degrees C produced an opening of the BBB but the duration of the opening was less than 30 min. We then investigated the effect of an Na(+)/Ca(2+) exchange blocker (KB-R7943) on this hypothermic BBB opening. KB-R7943 extended the BBB opening to 30 min without affecting the peak level of BBB permeability at 5 min. Simple manipulation of temperature can thus enhance the reversible BBB opening in mannitol and pharmacological manipulation of calcium dynamics works synergistically with hypothermic mannitol. ©2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855842     DOI: 10.1006/bbrc.2002.6495

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 2.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

3.  Collagen-based brain microvasculature model in vitro using three-dimensional printed template.

Authors:  Jeong Ah Kim; Hong Nam Kim; Sun-Kyoung Im; Seok Chung; Ji Yoon Kang; Nakwon Choi
Journal:  Biomicrofluidics       Date:  2015-04-15       Impact factor: 2.800

4.  Mannitol Augments the Effects of Systemical Stem Cell Transplantation without Increasing Cell Migration in a Stroke Animal Model.

Authors:  Sang-Hoon Lee; Ho-Young Kang; Jong-Hoon Kim; Dong-Hyuk Park
Journal:  Tissue Eng Regen Med       Date:  2020-09-08       Impact factor: 4.169

Review 5.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

Review 6.  Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier.

Authors:  Gabriel S Gonzales-Portillo; Paul R Sanberg; Max Franzblau; Chiara Gonzales-Portillo; Theo Diamandis; Meaghan Staples; Cyndy D Sanberg; Cesar V Borlongan
Journal:  Cell Transplant       Date:  2014-01-29       Impact factor: 4.064

7.  Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier.

Authors:  Bruno M D C Godinho; Nils Henninger; James Bouley; Julia F Alterman; Reka A Haraszti; James W Gilbert; Ellen Sapp; Andrew H Coles; Annabelle Biscans; Mehran Nikan; Dimas Echeverria; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Mol Ther       Date:  2018-08-08       Impact factor: 11.454

Review 8.  Drug and gene delivery across the blood-brain barrier with focused ultrasound.

Authors:  Kelsie F Timbie; Brian P Mead; Richard J Price
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

Review 9.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

10.  A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).

Authors:  Ronit Shaltiel-Karyo; Moran Frenkel-Pinter; Edward Rockenstein; Christina Patrick; Michal Levy-Sakin; Abigail Schiller; Nirit Egoz-Matia; Eliezer Masliah; Daniel Segal; Ehud Gazit
Journal:  J Biol Chem       Date:  2013-05-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.